Study of the glycogenolytic action of platelet activating factor in Tetrahymena pyriformis.
1. A novel action of AGEPC on non-inflammatory cells was revealed, namely the ability to stimulate glycogenolysis in Tetrahymena pyriformis cells. 2. The glycogenolytic effect of AGEPC seems to be dependent on Ca2+ transport and regulation, thus the effects are completely inhibited by Verapamil and partially by EGTA. 3. The influence of Propranolol, Labetalol, Atenolol and Theophylline in the glycogenolytic effect of AGEPC are also studied. 4. Our findings suggest that the AGEPC promoted glycogenolysis in Tetrahymena through a mechanism distinct from that of catecholamines.
Tsangaris
G T
GT
Department of Chemistry, University of Athens, Greece.
Demopoulos
C A
CA
Tsoukatos
D C
DC
Kapoulas
V M
VM
D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D002118:Calcium / Q000502:physiology; D000242:Cyclic AMP / Q000502:physiology; D005947:Glucose / Q000096:biosynthesis; D006003:Glycogen / Q000378:metabolism*; D007741:Labetalol / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D013769:Tetrahymena pyriformis / Q000187:drug effects / Q000378:metabolism*
D010972:Platelet Activating Factor; D001262:Atenolol; D006003:Glycogen; D011433:Propranolol; D000242:Cyclic AMP; D005947:Glucose; D007741:Labetalol; D002118:Calcium